vs

Side-by-side financial comparison of Ramaco Resources, Inc. (METC) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.

Orthofix Medical Inc. is the larger business by last-quarter revenue ($219.9M vs $121.0M, roughly 1.8× Ramaco Resources, Inc.). Orthofix Medical Inc. runs the higher net margin — -1.0% vs -11.0%, a 10.0% gap on every dollar of revenue. On growth, Orthofix Medical Inc. posted the faster year-over-year revenue change (2.0% vs -27.7%). Orthofix Medical Inc. produced more free cash flow last quarter ($16.8M vs $-17.5M). Over the past eight quarters, Orthofix Medical Inc.'s revenue compounded faster (8.0% CAGR vs -22.7%).

Ramaco Resources, Inc. is a U.S.-based mining company focused on high-grade metallurgical coal production. It operates mining assets across the Appalachian region, supplying products to global steel manufacturing and industrial clients, with core operations centered on sustainable low-cost metallurgical coal extraction and distribution.

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

METC vs OFIX — Head-to-Head

Bigger by revenue
OFIX
OFIX
1.8× larger
OFIX
$219.9M
$121.0M
METC
Growing faster (revenue YoY)
OFIX
OFIX
+29.7% gap
OFIX
2.0%
-27.7%
METC
Higher net margin
OFIX
OFIX
10.0% more per $
OFIX
-1.0%
-11.0%
METC
More free cash flow
OFIX
OFIX
$34.4M more FCF
OFIX
$16.8M
$-17.5M
METC
Faster 2-yr revenue CAGR
OFIX
OFIX
Annualised
OFIX
8.0%
-22.7%
METC

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
METC
METC
OFIX
OFIX
Revenue
$121.0M
$219.9M
Net Profit
$-13.3M
$-2.2M
Gross Margin
15.8%
71.1%
Operating Margin
-12.0%
0.2%
Net Margin
-11.0%
-1.0%
Revenue YoY
-27.7%
2.0%
Net Profit YoY
-5468.2%
92.4%
EPS (diluted)
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
METC
METC
OFIX
OFIX
Q4 25
$219.9M
Q3 25
$121.0M
$205.6M
Q2 25
$153.0M
$203.1M
Q1 25
$134.7M
$193.6M
Q4 24
$170.9M
$215.7M
Q3 24
$167.4M
$196.6M
Q2 24
$155.3M
$198.6M
Q1 24
$172.7M
$188.6M
Net Profit
METC
METC
OFIX
OFIX
Q4 25
$-2.2M
Q3 25
$-13.3M
$-22.8M
Q2 25
$-14.0M
$-14.1M
Q1 25
$-9.5M
$-53.1M
Q4 24
$3.9M
$-29.1M
Q3 24
$-239.0K
$-27.4M
Q2 24
$5.5M
$-33.4M
Q1 24
$2.0M
$-36.0M
Gross Margin
METC
METC
OFIX
OFIX
Q4 25
71.1%
Q3 25
15.8%
72.2%
Q2 25
12.3%
68.7%
Q1 25
15.2%
62.8%
Q4 24
20.4%
69.0%
Q3 24
19.5%
68.7%
Q2 24
21.0%
67.8%
Q1 24
19.1%
67.5%
Operating Margin
METC
METC
OFIX
OFIX
Q4 25
0.2%
Q3 25
-12.0%
-8.3%
Q2 25
-9.1%
-7.9%
Q1 25
-8.9%
-25.2%
Q4 24
3.7%
-5.3%
Q3 24
1.0%
-9.6%
Q2 24
3.5%
-12.5%
Q1 24
1.9%
-15.6%
Net Margin
METC
METC
OFIX
OFIX
Q4 25
-1.0%
Q3 25
-11.0%
-11.1%
Q2 25
-9.1%
-6.9%
Q1 25
-7.0%
-27.4%
Q4 24
2.3%
-13.5%
Q3 24
-0.1%
-13.9%
Q2 24
3.6%
-16.8%
Q1 24
1.2%
-19.1%
EPS (diluted)
METC
METC
OFIX
OFIX
Q4 25
$-0.05
Q3 25
$-0.57
Q2 25
$-0.36
Q1 25
$-1.35
Q4 24
$0.06
$-0.76
Q3 24
$-0.03
$-0.71
Q2 24
$0.08
$-0.88
Q1 24
$0.00
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
METC
METC
OFIX
OFIX
Cash + ST InvestmentsLiquidity on hand
$193.8M
$82.0M
Total DebtLower is stronger
$116.3M
Stockholders' EquityBook value
$526.9M
$450.0M
Total Assets
$849.7M
$850.6M
Debt / EquityLower = less leverage
0.22×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
METC
METC
OFIX
OFIX
Q4 25
$82.0M
Q3 25
$193.8M
$62.9M
Q2 25
$28.1M
$65.6M
Q1 25
$43.5M
$58.0M
Q4 24
$33.0M
$83.2M
Q3 24
$22.9M
$30.1M
Q2 24
$27.6M
$26.4M
Q1 24
$30.5M
$27.0M
Total Debt
METC
METC
OFIX
OFIX
Q4 25
Q3 25
$116.3M
$157.2M
Q2 25
$157.0M
Q1 25
$156.9M
Q4 24
$88.2M
$157.0M
Q3 24
$118.5M
Q2 24
$118.0M
Q1 24
$118.2M
Stockholders' Equity
METC
METC
OFIX
OFIX
Q4 25
$450.0M
Q3 25
$526.9M
$442.5M
Q2 25
$347.4M
$458.3M
Q1 25
$355.2M
$458.3M
Q4 24
$362.8M
$503.1M
Q3 24
$361.8M
$525.9M
Q2 24
$366.1M
$546.0M
Q1 24
$372.3M
$570.3M
Total Assets
METC
METC
OFIX
OFIX
Q4 25
$850.6M
Q3 25
$849.7M
$832.6M
Q2 25
$674.6M
$837.2M
Q1 25
$685.7M
$823.1M
Q4 24
$674.7M
$893.3M
Q3 24
$645.4M
$867.9M
Q2 24
$659.2M
$882.0M
Q1 24
$674.0M
$906.0M
Debt / Equity
METC
METC
OFIX
OFIX
Q4 25
Q3 25
0.22×
0.36×
Q2 25
0.34×
Q1 25
0.34×
Q4 24
0.24×
0.31×
Q3 24
0.23×
Q2 24
0.22×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
METC
METC
OFIX
OFIX
Operating Cash FlowLast quarter
$-1.4M
$27.7M
Free Cash FlowOCF − Capex
$-17.5M
$16.8M
FCF MarginFCF / Revenue
-14.5%
7.6%
Capex IntensityCapex / Revenue
13.3%
4.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-24.7M
$-1.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
METC
METC
OFIX
OFIX
Q4 25
$27.7M
Q3 25
$-1.4M
$12.4M
Q2 25
$-4.3M
$11.6M
Q1 25
$26.0M
$-18.4M
Q4 24
$15.7M
$23.7M
Q3 24
$37.4M
$11.7M
Q2 24
$34.4M
$9.0M
Q1 24
$25.2M
$-18.6M
Free Cash Flow
METC
METC
OFIX
OFIX
Q4 25
$16.8M
Q3 25
$-17.5M
$2.5M
Q2 25
$-19.8M
$4.5M
Q1 25
$7.6M
$-25.1M
Q4 24
$5.1M
$15.2M
Q3 24
$25.6M
$6.3M
Q2 24
$20.3M
$-360.0K
Q1 24
$6.5M
$-29.1M
FCF Margin
METC
METC
OFIX
OFIX
Q4 25
7.6%
Q3 25
-14.5%
1.2%
Q2 25
-13.0%
2.2%
Q1 25
5.6%
-13.0%
Q4 24
3.0%
7.0%
Q3 24
15.3%
3.2%
Q2 24
13.1%
-0.2%
Q1 24
3.7%
-15.4%
Capex Intensity
METC
METC
OFIX
OFIX
Q4 25
4.9%
Q3 25
13.3%
4.8%
Q2 25
10.2%
3.5%
Q1 25
13.7%
3.5%
Q4 24
6.2%
4.0%
Q3 24
7.0%
2.7%
Q2 24
9.1%
4.7%
Q1 24
10.8%
5.6%
Cash Conversion
METC
METC
OFIX
OFIX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
4.06×
Q3 24
Q2 24
6.21×
Q1 24
12.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

METC
METC

Export Coal Revenues$73.0M60%
Domestic Coal Revenues$48.0M40%

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

Related Comparisons